Abstracts

577 – HIV-1/Mtb Coinfection Selects for bNAb-Resistant Envelopes Revealed by Droplet PCR Sequencing

Background People living with HIV and active tuberculosis (PWH/TB) generate more broadly potent HIV-1 neutralizing antibodies as compared to those PWH/No TB (Bukola et al.). Enhanced neutralizing antibody responses, together with rapid viral diversification, can favor the emergence of neutralization resistant HIV-1 envelopes. We hypothesize that PWH/TB as compared to PWH/No TB harbor more broadly…

581 – HIV-1 Susceptibility to Lenacapavir Is Not Affected by Capsid Protein Polymorphisms T107A and T107S

Background Lenacapavir (LEN) is the first-in-class twice-yearly long-acting HIV-1 capsid inhibitor approved for treating multidrug-resistant HIV-1, as well as for pre-exposure prophylaxis (PrEP) in people who could benefit from PrEP.  In heavily treatment-experienced people with HIV (PWH), LEN resistance mutations have been observed in the context of LEN functional monotherapy. One such mutation, T107N, is…

592 – Uncovering Occult HBV Replication in People With HIV Using High-Sensitivity HBcrAg Assay

Background People with HIV (PWH) are at increased risk of co-infection with hepatitis B virus (HBV). With the increasing use of antiretroviral regimens that lack anti-HBV activity, the risk of HBV reactivation has become a renewed concern. Occult HBV infection is particularly difficult to identify in patients with isolated anti-HBc, as conventional serological markers often…

594 – Low-Frequency Minority Variants of Hepatitis B Virus Are Associated With Immune Escape Mutations

Background The hepatitis B virus (HBV) is characterised by extensive genetic diversity, including low-frequency minority variants that contribute to disease progression. While these variants represent a critical component of the viral genome pool, their role is often underestimated due to limitations in detection. We therefore characterized low-frequency minority variants associated with drug resistance and immune escape mutations and evaluated their potential…

609 – HIV Status Drives Distinct Immune Pathways of Persistent Portal Hypertension After HCV Cure

Background Persistent portal hypertension after hepatitis C virus (HCV) cure remains a major determinant of prognosis in advanced cirrhosis, yet its immune drivers are poorly defined, particularly in people with HIV (PWH). Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal hypertension and a strong predictor of outcomes. Despite high rates of…

888 – Optimizing HIV Prevention in South Africa: Spatial Patterns of HIV Incidence From Routine Data

Background Novel HIV prevention methods such as injectable lenacapavir (LEN) will have the greatest impact by reaching populations at the greatest HIV risk in the highest incidence areas. However, incidence is not directly measurable at small geographic scales. We explored relative HIV incidence proxy measures, calculated from routine service delivery data, to identify subdistricts for…

637 – Immunotherapy Treatment Receipt and Outcomes Among People Living With HIV and Lung Cancer

Background Immunotherapy has revolutionized lung cancer management. However, people with HIV (PWH) are often excluded from immunotherapy trials, which limit real-world evidence on effectiveness of immunotherapy among these patients. Thus, our objective was to assess the effect of immunotherapy on overall survival among lung cancer patients, stratified by HIV status.  Methods We conducted a retrospective…

542 – Ibalizumab Demonstrates Real-World Durability in People Living With Multidrug Resistant HIV

Background There are ~1.2 million people with HIV (PWH) in the United States. Among them, ~1% are heavily treatment-experienced (HTE) and harbor multidrug-resistant (MDR) HIV-1. MDR HIV-1 is most observed in individuals with extensive prior exposure to antiretroviral therapies (ARVs). For this underrepresented and clinically complex population, achieving and sustaining virologic suppression remains a significant…

552 – Next-Generation Sequencing of HIV Resistance in Dolutegravir Failure Under Variable Drug Pressure

Background In South Africa (SA), virological failure on dolutegravir (DTG)-based regimens is often driven by suboptimal adherence. Next-generation sequencing (NGS) may detect resistance mutations more sensitively than conventional Sanger sequencing. We investigated the added value of NGS in samples with and without detectable DTG drug pressure. Methods  We established an IonTorrent AmpliSeq HIVDR NGS workflow…